Frontrunner in Therapies for Complement- Mediated Diseases

Based on the research of the company's founders, Simon Clark, Paul Bishop, and Richard Unwin from the University of Manchester, CTx aims to develop innovative and effective therapeutics to address unmet needs in complement-mediated diseases, particularly in the fields of age-related macular deg...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical technology Europe 2023-07, Vol.35 (7), p.11-12
Main Author: Piachaud-Moustakis, Bianca
Format: Article
Language:English
Subjects:
Atrophy
Competition
Disease
Funding
Immune system
Innovations
Laboratories
Macular degeneration
Patients
Pharmaceutical industry
Precision medicine
R&D
Research & development
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Based on the research of the company's founders, Simon Clark, Paul Bishop, and Richard Unwin from the University of Manchester, CTx aims to develop innovative and effective therapeutics to address unmet needs in complement-mediated diseases, particularly in the fields of age-related macular degeneration (AMD), kidney disease, and various haematological conditions. According to Rafiq Hasan, CEO and managing director at Complement Therapeutics GmbH, "the support of this broad syndicate enables us to generate additional data demonstrating CTx001's unique and differentiated mechanism of action, with the potential to transform the treatment landscape in [GA]" (9). According to the US National Eye Institute (NEI), dry AMD has three stages: early, intermediate, and late, with the disease usually progressing slowly over several years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of complement therapeutics is likely to expand further with the market poised to witness steady growth over the coming years.
ISSN:1753-7967